Eiger BioPharmaceuticals to focus Avexitide for hyperinsulinemic hypoglycaemia indicationsEiger BioPharmaceuticals has revealed it will focus its development efforts on advancing avexitide in hyperinsulinemic hypoglycaemia...
Use of avexitide in patients with post-bariatric hypoglycaemia and hyperinsulinemic hypoglycaemiaPhase 2b results of avexitide (Eiger BioPharmaceuticals) in patients with post-bariatric hypoglycemia (PBH) and hyperinsulinemic...
PREVENT Study: Positive results of Avexitide in post-bariatric hypoglycaemia patientsEiger BioPharmaceuticals has announced positive results from the Phase 2 PREVENT study of Avexitide in patients with severe...
LSG and RYGB-induced upregulation of apoA-IV is beneficial for insulin secretion and energy expenditure2 days ago
Tirzepatide reduced sleep apnoea severity by up to nearly two-thirds in adults living with OSA and obesity2 days ago